Vanda rises after FDA grants rare hearing on jet‑lag drug bid

Vanda Pharmaceuticals

03/03/2026 13:36

** Shares of drugmaker Vanda Pharmaceuticals VNDA.O rise 2.2% to $8.35 premarket

** Company says FDA will hold a rare public hearing to review its bid to expand sleep drug Hetlioz for jet‑lag disorder

** Jet lag occurs when long‑distance travel disrupts the body’s internal clock, causing fatigue and poor sleep

** VNDA says this is the first such drug‑approval hearing in more than 40 years and follows its appeal after FDA initially refused the application

** Hetlioz is already approved for two rare sleep disorders

** VNDA shares up ~84% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))